DIRS.INFO The most relevant business & tech news

☆ Recent weakness in this energy company's shares offer an 'attractive' entry point, BMO says
▼ + stars: | 2023-09-14 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

The recent pullback in First Solar shares has created an attractive entry point, according to BMO Capital Markets. Analyst Ameet Thakkar upgraded shares to outperform from market perform. "FSLR stock has declined by an unwarranted degree following its recent Analyst Day in our view. Underperformance has accelerated since the company's positive analyst day on Sept. 7, with the stock losing about 5% since. BMO views First Solar as a winner under the Inflation Reduction Act, which it believes will help the company's earnings power.

Persons: Ameet, Thakkar, Underperformance, — CNBC's Michael Bloom Organizations: BMO Capital Markets, BMO, U.S, PTC Locations: Wednesday's

☆ Amazon is quietly building a publisher-focused ad product team to grow its $37 billion ad business
▼ + stars: | 2023-08-11 | by ( Lauren Johnson | ) www.businessinsider.com time to read: +3 min

The tech will help publishers sell ads on and off Amazon, according to job postings. The retail giant has 11 job postings for a new team called "PubTech" that will be part of Amazon Ads. The Amazon Ads' team is building products for first-party publishers that have channels on Amazon — like Twitch, FireTV, and Freevee — as well as third-party web publishers, according to the job listings. While Amazon does help publishers sell ads through a unit called Amazon Publisher Services, that unit is not part of Amazon Ads, and those services require publishers work with third-party SSPs. The core of Amazon's $37 billion ad business are search ads, and its ad division has mostly focused on building tools for advertisers.

Persons: Twitch, Freevee —, Ameet Shah, Magnite Organizations: Amazon, Google, PubTech, Ads, Amazon Publisher Services, Prohaska Consulting, Exchange, Microsoft, Trade Locations: what's

☆ Launch of arthritis drug biosimilars ramps up US pressure on pricing 'middlemen'
▼ + stars: | 2023-07-25 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

Seven drugmakers this month launched their own versions, known as biosimilars, of AbbVie's (ABBV.N) flagship arthritis drug Humira, once the world's top-selling prescription medicine. Three have kept their list price within 5%-7% of AbbVie's, two priced at an 85% discount and two have offered both types of prices. For insured patients who are often on the hook for co-pays of 10% to 25% of the list price, the savings have been minimal. Reuters GraphicsThe Biden administration has made lowering drug prices a priority. Amgen offered 5% and 55% discounts to AbbVie's $6,922 per month Humira price tag, and both were included on drug coverage lists at two large PBMs.

Persons: Dado Ruvic, Humira, Ameet Sarpatwari, Biden, PBMs, Cigna, UnitedHealth, Amgen, Robin Feldman, Ron Wyden, Wyden, Chuck Grassley, Grassley, Patrick Wingrove, Moira Warburton, Josephine Walker, Caroline Humer, Bill Berkrot Organizations: REUTERS, Association for Accessible Medicines, Harvard Medical School, Reuters, Lawmakers, Federal Trade Commission, FTC, CVS, Biosimilars, Healthcare, Novartis, Sandoz, Reuters Graphics Reuters, University California College of the, Democratic, Republican, Thomson Locations: U.S, Humira, San Francisco, New York, Washington

The residential solar panel company has outperformed both the Invesco Solar ETF and the S & P 500 in 2023. Sunnova shares are up 25%, while the fund has lost 2%. NOVA YTD mountain Sunnova Energy shares "We remain constructive on NOVA and residential solar growth in the U.S. longer-term. That said, the macro backdrop for U.S. residential solar remains challenging," Thakkar wrote in a Friday note. "Dealer growth has been a key driver of success in a difficult environment.

Persons: Ameet Thakkar, Thakkar, Sunnova, — CNBC's Michael Bloom Organizations: Sunnova Energy, BMO, NOVA, Treasury Locations: U.S

☆ Merck sues US government to halt Medicare drug price negotiation
▼ + stars: | 2023-06-06 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

NEW YORK, June 6 (Reuters) - Merck & Co (MRK.N) sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues is violates the Fifth and First Amendments to the U.S. Constitution. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for Medicare. Merck called the talks with CMS coercive and forces drugmakers to participate in "political Kabuki theater" by pretending negotiations are voluntary. The first ever Medicare drug price reduction process is due to begin in September when CMS identifies its 10 most costly drugs. Merck's top selling drug, cancer immunotherapy Keytruda, could be subject to negotiations as soon as 2028.

Persons: drugmakers, Merck, Ameet, Robin Feldman, Wells, Mohit Bansal, Xavier Becerra, Chiquita Brooks, Michael Erman, Patrick Wingrove, Edwina Gibbs, Nick Zieminski Organizations: YORK, Merck & Co, U.S, U.S . Constitution, Biden, Medicare, District of Columbia, Merck, Reuters, CMS, Harvard Medical School, UC College of the, Supreme, U.S . Department of Health & Human Services, Centers, Medicaid Services, LaSure, HHS, Thomson Locations: U.S ., U.S, San Francisco

☆ Who's going to work on all these AI projects at the big banks?
▼ + stars: | 2023-05-24 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +5 min

Everyone seems to agree that artificial intelligence is going to upend Wall Street. Insider's Paige Hagy and Bianca Chan have a fascinating story on how AI talent doesn't seem to be sticking around at big banks. What's even more foreboding is that AI talent isn't leaving for other banks. But struggling to hold on to AI talent seems especially concerning when one considers what's at stake — like, uh, humanity — and the speed at which it'll happen. Here are the three reasons banks can't seem to hold on to AI talent.

☆ New York Magazine cut digital ads on abortion-related content so readers wouldn't be tracked — showing the challenges publishers face post-Roe v. Wade
▼ + stars: | 2022-10-31 | by ( Elizabeth Pham Janowski | ) www.businessinsider.com time to read: +4 min

Vox Media, which owns the magazine, pulled ads from the digital versions of the articles to protect readers from being tracked. Walton told Insider that Vox Media made the decision because the priority was to "provide a utility and service" to their audience. Vox Media declined to comment on the financial loss from pulling ads and removing the paywall. Shah said that in his view, Vox Media took all reasonable measures to mitigate reader privacy risks by pulling digital ads. Shah agreed that these ad products minimize opportunities for readers' data to leak out to third parties.

☆ New York Magazine axed digital ads on abortion-related content so readers wouldn't be tracked — and it shows the new challenges publishers face post-Roe v. Wade.
▼ + stars: | 2022-10-28 | by ( Elizabeth Pham Janowski | ) www.businessinsider.com time to read: +4 min

☆ Layoffs, lost sales, and revised business plans: How a Facebook tech glitch is wreaking havoc for advertisers around the world
▼ + stars: | 2022-09-27 | by ( Lara O'Reilly | ) www.businessinsider.com time to read: +6 min

A technical glitch continues to ban Meta ad accounts at random. But three weeks ago, business ground to a halt when Color Crush Book's Facebook ad account was unexpectedly terminated. The founders of Color Crush Books said they're considering shifting from their digital-only model after experiencing Facebook ad account issues. The company's Meta ad account was reinstated on Tuesday after Insider contacted Meta. Silverbird's ad account was disabled in mid-August and Lorenzos shifted some of the budget to search and offline channels.

Search resuls for: "Ameet"

9 mentions found